NCT03754530View on ClinicalTrials.gov

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

PHASE2UnknownINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

June 1, 2020

Study Completion Date

December 1, 2021

Conditions
Non-Small Cell Lung CancerBrain Metastases
Interventions
DRUG

Icotinib

orally three times per day

RADIATION

WBRT or SRS

\>3 with WBRT;\<=3 with SRS

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT03754530 - Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | Biotech Hunter | Biotech Hunter